BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026)
BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 1,301.00 |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | 331.00 |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -667.00 |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 480.00 |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -254.00 |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 1,342.00 |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 1,902.00 |
| 10 | BioXcel Therapeutics | 20.04 Mn | 20.04 Mn | -77,000.00 | 43,509.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,509.00 |
| Dec 31, 2025 | 63,919.00 |
| Sep 30, 2025 | 207,555.00 |
| Jun 30, 2025 | 437,439.00 |
| Mar 31, 2025 | -35,852.00 |
| Dec 31, 2024 | -26,874.00 |
| Sep 30, 2024 | -20,273.00 |
| Jun 30, 2024 | -19,157.00 |
| Mar 31, 2024 | -26,373.00 |
| Dec 31, 2023 | -24,939.00 |
| Sep 30, 2023 | -20,292.00 |
| Jun 30, 2023 | -6,886.00 |
| Mar 31, 2023 | -2,491.00 |
| Dec 31, 2022 | 2,345.00 |
| Sep 30, 2022 | 4,603.00 |
| Jun 30, 2022 | 3,966.00 |
| Mar 31, 2022 | 1,220.00 |
| Dec 31, 2021 | 288.00 |
| Sep 30, 2021 | -776.00 |
| Jun 30, 2021 | -2,279.00 |